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Resolved Psoriasis Lesions Retain Expression
of a Subset of Disease-Related Genes
Mayte Sua´rez-Farin˜as1,2, Judilyn Fuentes-Duculan1, Michelle A. Lowes1 and James G. Krueger1
Psoriasis is a complex inflammatory disease that usually heals without visible scarring. Histological evaluation
often suggests complete resolution, but reversal of genomic disease-associated alterations has not yet been
defined. Gene expression profiling was used to determine the extent to which the psoriasis genes were
reversed after 3 months of etanercept treatment in patients who responded to treatment. We reviewed the
histology, leukocyte counts, and PCR data for inflammatory genes, to compare recovery of these parameters and
the genomic studies. Many cellular markers do return close to nonlesional levels, although five inflammatory
genes did not improve by 475% (IL-12p35, MX1, IL-22, IL-17, and IFNg). Psoriasis-related genes with o75%
improvement were defined as comprising a ‘‘residual disease genomic profile,’’ composed of 248 probe sets.
Genes of interest in psoriasis tissue that did not return to baseline included LYVE-1, WNT5A, RAB31, and AQP9.
It appears that even when the epidermal reaction in psoriasis is fully resolved, inflammation, as defined by
expression of key cytokines and chemokines, is not completely resolved in treated lesions. We also found that
structural cells of the skin continued to express molecular alterations, and that some subtle features of skin
structure, for example, lymphatics, were not fully normalized with treatment.
Journal of Investigative Dermatology (2011) 131, 391–400; doi:10.1038/jid.2010.280; published online 23 September 2010
INTRODUCTION
Psoriasis is a complex inflammatory disease with a char-
acteristic clinical and histological phenotype. The non-
affected skin of psoriasis patients does not appear to have
any distinct clinical features, and effective treatment returns
lesional (LS) skin to a nonlesional (NL) state, that is, skin
that appears virtually normal. Our past studies with several
different therapies for psoriasis suggest that successful
treatment is correlated with reduced epidermal thickness
and reductions in inflammatory cellular infiltrates and gene
expression (Chamian et al., 2005; Zaba et al., 2007). We
have shown that in patients responding to therapy, the
cellular infiltrate and expression of selected inflammatory
genes in affected LS skin return to NL levels at the end of
treatment. The clinical appearance, combined with histolo-
gical and molecular studies, indicated that psoriasis skin
lesions were reversed without obvious differences to NL skin.
Thus psoriasis can be viewed as ‘‘reversible’’ when the
inflammation is removed from the skin.
Although psoriasis may recur in new areas, it is well
recognized that it often recurs in the same locations on the
body, which may suggest that the skin where psoriasis lesions
were observed is not fully ‘‘healed.’’ There may be some
residual changes in treated lesions that predispose to
recurrence of lesions in the same locations. However,
histopathology does not give a good indication of cell
function, and PCR studies have been conducted on a small
group of selected genes. The introduction of microarray
profiling has given a more comprehensive platform to study
disease-specific genes and how they respond to treatment.
We wanted to determine the extent to which the genomic
psoriasis phenotype, as defined by the differentially expressed
genes (DEGs) between LS and NL skin, was reversed by
etanercept treatment in responding patients. At the end of the
3-month clinical trial period, we analyzed how closely the
psoriasis transcriptome returned to a NL state in responders.
We were interested to see whether psoriasis was fully
reversible at the molecular level when the skin was clinically
clear of disease. Although many DEGs were normalized in
posttreatment biopsies, 248 genes did not return to baseline
(NL) after 3 months of treatment. We have termed this
residual genomic expression that did not return to NL levels
as ‘‘residual disease genomic profile (RDGP).’’ This gene set
has important implications for the biology and treatment of
psoriasis, and it could serve as a means to study progressive
alterations in skin structure and function as a consequence of
temporal progression or severity of skin lesions.
RESULTS
Resolution of psoriasis lesions
Much of clinical disease pathology in psoriasis is related to
altered epidermal growth and differentiation. In this analysis,
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we sought to relate epidermal improvement to modulation of
disease-related genes by etanercept. In the group of patients
that respond to etanercept, the epidermis was almost fully
recovered (Table 1). The epidermal thickness improved by
92% on average, Ki67 (a marker of cellular proliferation)
improved by 119%, keratin 16 mRNA improved by 100%,
and all cases were keratin 16 negative by immunohisto-
chemistry (Zaba et al., 2007). Hence, to a pathologist using
hematoxylin and eosin stain or growth-related markers, the
epidermis would appear histologically ‘‘normal.’’
To determine the extent to which the inflammatory
infiltrate and specific inflammatory genes improved with
treatment, we calculated the mean improvement in cell
counts (Table 1). CD3þ T cells almost completely returned to
baseline (95.5% improvement); CD8þ T cells were improved
by 77%; CD11cþ myeloid dendritic cells (DCs) were
improved by 88%; CD83þ mature DCs were improved by
121%; and CD163þ macrophages were improved
by 97%. CD206 is on both DCs and macrophages and
was improved by 84%, and DC-LAMPþ mature DCs were
improved by 100%. Overall, resolution of inflammatory
cell populations in the epidermis was often higher than
the dermis, although both were improved by 475% for all
Table 1. Improvement of cell counts and RT-PCR data
for 11 responding patients
Symbol LS vs NL W12 vs 0 % Improvement
Epidermis
Original thickness 245.67 224.51 91.39
Ki67 cell counts 122.13 145.00 118.7
K16 mRNA 5.06 5.05 99.86
K16 histology 100% were K16
Cells1
CD3 (T cells)
Total 145.12 138.59 95.5
Epidermis 51.27 54.29 105.91
Dermis 80.87 84.29 104.24
CD8 (cytotoxic T cells)
Total 126.83 96.50 76.80
Epidermis 60.33 54.67 90.80
Dermis 65.67 41.83 63.71
CD11c (myeloid DCs)
Total 216.59 197.47 88.4
Epidermis 47.69 47.41 99.42
Dermis 168.88 144.06 85.31
CD83 (mature DCs)
Total 7.24 8.76 121.14
Epidermis 1.76 2.35 133.33
Dermis 5.47 6.41 117.20
CD163 (macs)
Total 68.94 66.82 96.93
Epidermis — — —
Dermis 64.13 66.82 104.19
CD206 (DCs, macs)
Total 167.12 140.41 84.02
Epidermis 9.87 8.76 88.83
Dermis 145.07 131.65 90.75
DCLAMP (mature DCs)
Total 48.59 48.71 100.24
Epidermis 5.13 4.65 90.53
Dermis 42 44.06 104.90
Table 1. Continued
Symbol LS vs NL W12 vs 0 % Improvement
Genes
LTA.1 0.37 2.34 623.75
IL-4 1.15 1.80 156.66
CCL3 3.17 4.75 149.87
CCL4 2.94 3.92 133.26
AREG 2.16 2.86 132.56
IL-19 5.35 6.11 114.27
IL-6 2.88 3.13 108.61
IL-1b 4.04 4.08 101.03
p40 3.83 3.55 92.82
IL-8 6.75 6.07 89.82
iNOS 6.37 5.54 87.00
IL-20 3.72 3.13 84.22
b-Defensin 4.08 3.34 81.81
IL23p19 3.09 2.49 80.77
CCL20 3.31 2.67 80.72
IL12p35 1.58 1.07 67.43
MX-1 3.67 2.42 66.06
IL-22 3.60 2.34 65.09
IL-17 6.16 3.92 63.66
IFN-g 2.26 1.41 62.22
Abbreviations: DC, dendritic cell; K16, keratin 16; LS, lesional; macs,
macrophages; NL, nonlesional; RT-PCR, reverse transcriptase PCR; W, week.
1Cell counts were summarized across patients for the total, epidermal, and
dermal counts; hence, the average of the total does not add up to the average
of the epidermis and dermis.
Bold values indicate genes that improved o75%.
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populations studied, except dermal CD8þ cells, which
improved only by 64%.
In Table 1, improvement of selected genes by reverse
transcriptase PCR expression in responding patients is
presented. Five genes that did not improve by 475% were
important proinflammatory genes, IL-12p35, MX1, IL-22,
IL-17 and IFN-g (range of improvement was 62–67%). Hence,
while within resolved skin pathological T cells were 495%
reduced based on CD3þ cell counts, dermal CD8þ cells
were not fully resolved, and some T-cell activation may be
ongoing within residual infiltrates. Overall, we interpret these
findings to indicate that the epidermis can improve almost
completely even in the context of some residual inflamma-
tory gene expression.
Resolution of psoriasis disease-related genes
Our first publication of the genomic data from this group of
patients (n¼ 15) described the genomic effects of etanercept in
responders and nonresponders (Zaba et al., 2009b). We have
also defined the psoriasis transcriptome using these patients
and compared with other published psoriasis DEG lists (Sua´rez-
Farin˜as et al., 2010). Our psoriasis-related DEG contained 732
upregulated probe sets (579 known unique genes) and 890
downregulated probe sets (703 genes) (Figure 1a). Here, we
considered the psoriasis phenotype as genomically defined by
these DEG and used them to determine the extent to which the
psoriasis phenotype was reversed after 3 months of etanercept
treatment in 11 patients who responded to the treatment.
Indeed, our analysis showed that a large set of disease-related
genes was improved by 490%, and some genes had
improvement even beyond NL levels. A selection of improved
psoriasis genes is presented in Table 2, and full list in
Supplementary Table S1 online. Many inflammatory genes
such as granzyme B, IL-8, and S100A8 improved by 91%.
Structural genes, such as keratin 6B and 16, as well as
epidermal protein lipocalin 2 (LCN2) also improved by496%.
Resolution of gene sets representing specific cells (Haider
et al., 2007; Guttman-Yassky et al., 2009; Zaba et al., 2010)
could also be evaluated using a gene set approach (Table 3).
For example upregulated keratinocyte genes were improved
by 4105%, and upregulated T-cell genes by B88%. Sets
representing myeloid cell populations, including immature
and mature DCs, inflammatory myeloid DCs, and macro-
phages, all improved by 489%.
Defining RDGP in treated psoriasis
Genes witho75% improvement were defined as comprising
the RDGP. From the psoriasis upregulated genes, 76 probe
sets (64 genes) did not improve above 75% with treatment,
and among disease downregulated genes, 206 probe sets
(184 genes) showed below 75% improvement (Figure 1a). A
selection of potentially interesting genes that did not return to
NL levels is presented in Table 4, for both up- and
downregulated psoriasis genes (see Supplementary Table S1
online for complete RDGP). These genes identify a set of
disease-related genes with incomplete reversal even after
effective therapy. Unfortunately, many primary cytokines
such as IFNg, IL-17, IL-22, are not reliably detected by
Affymetrix chips owing to low mRNA abundance (Sua´rez-
Farin˜as et al., 2010). As our definition of RDGP is based on
Affymetrix expression data, those genes are not presented in
Supplementary Table S1 online. However, as we have
assessed their improvement by PCR (Table 1), they could be
considered as residual genes in a broader definition of RDGP.
Within this RDGP, we consider two sets of effects. First,
there was continued expression of many inflammation-
related genes, possibly indicating incomplete suppression of
inflammatory circuits by etanercept. Genes such as lympho-
toxin and TCRb1 were upregulated in psoriasis and improved
byo75% (66 and 43% improvement, respectively). This is in
keeping with our observations described above, at the PCR
level, that epidermal improvement can occur even in the
setting of some continued inflammatory gene expression.
Structural changes in the skin
The second major effect that we considered within the RDGP
was the altered expression of genes associated with
‘‘structural’’ cell types of the skin. This suggests altered
physiology or tissue structure in resolved lesions, in some
Psoriasis disease-related
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Figure 1. Residual disease genomic profile. (a) Treatment response evaluated
in the set of psoriasis genes at fold change 42 and a false discovery rate of
0.05. Genes that improved 475% after 12 weeks of treatment were
considered part of ‘‘molecular resolution,’’ whereas those witho75% formed
the ‘‘molecular remnant.’’ (b) Example of treatment response of several genes.
The x-axis refers to time during the clinical trial, with response in the
nonlesional (NL) skin considered to be 0; Lesional (LS) skin levels showing
increase or decrease compared with NL skin levels, genes that at week 12
attain this line have an improvement of 100%. Upregulated psoriasis genes
WNT5, TCRb1, and RAB31 improved by o75% (red lines) and AQP9 and
LYVE1 were downregulated and improved by o75% (green lines). STAT1,
showed a complete remission of pathological expression (black line).
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sense, a ‘‘molecular scar.’’ Many of the genes that did not
return to NL levels were for structural cutaneous components.
There were genes that were downregulated during psoriasis
inflammation (LSoNL) that were not completely resolved by
week 12 (for example, LYVE-1 and AQP9). There were
upregulated genes that did not return to NL (for example,
RAB31 and WNT5A). Gene expression for these four genes is
shown in Figure 1b, and compared with STAT1, an
upregulated gene that did return to NL. We have also
performed immunohistochemistry for these four gene pro-
ducts from both down- and upregulated groups over the
treatment period (Figure 2).
LYVE-1, a well-recognized marker of lymphatic endo-
thelial cells, showed only 21% maximal improvement
at week 12. To determine the significance of persistent
downmodulation of LYVE-1 at the protein level, we
performed standard immunohistochemistry of LYVE-1 in
normal, NL, and LS skin samples, and at 12 weeks of
treatment (Figure 2a). In normal skin, the lymphatic vessels
identified by this antibody were mostly in the upper reticular
dermis and had a discernible (wide) lumen. In LS skin and at
week 12, the lymphatic vessels were more collapsed and
were observed to be closer to the dermo–epidermal junction
compared with NL skin. Hence, LYVE-1þ cells showed a
different pattern in normal skin compared with psoriatic
lesions, and even after treatment, it did not return to the
pattern of expression of normal skin.
WNT5A (wingless-related MMTV integration site 5A)
regulates epidermal differentiation in adult skin and acts in
synergistic induction of type-I IFN target genes (Romanowska
Table 2. Selected disease genes that have 490% improvement
Symbol Description LS vs NL W12 vs 0 Improvement (%)
GZMB Granzyme B 1.75 1.83 91.27
IL81 Interleukin 8 5.85 6.02 91.87
S100A8 S100 Calcium binding protein A8 1.73 1.51 91.96
CCL4 Chemokine (C–C motif) ligand 4 1.38 1.62 92.25
CCL18 Chemokine (C–C motif) ligand 18 1.48 1.79 92.43
IL19 Interleukin 19 1.43 2.08 92.50
IL1RN Interleukin 1 receptor antagonist 1.89 1.94 94.55
S100A9 S100 Calcium binding protein A9 3.90 3.59 94.59
IL1B1 Interleukin 1-b 2.61 3.22 95.94
IFI161 Interferon, g-inducible protein 16 1.08 0.90 96.31
KRT6B Keratin 6B 1.52 1.74 96.68
KRT16 Keratin 16 3.69 4.04 96.74
CCL20 Chemokine (C–C motif) ligand 20 2.79 3.71 96.81
SELE Selectin E 1.80 2.39 98.53
LAMP3 Lysosomal associated membrane protein 3 1.97 2.19 99.95
LCN2 Lipocalin 2 5.65 5.82 102.35
STAT1 Signal transducer and activator of transcription 1 1.41 1.35 102.62
TNFSF10 Tumor necrosis factor (ligand) superfamily 10 1.41 1.14 102.73
CCNF Cyclin F 1.17 1.25 104.33
MKi671 Antigen identified by monoclonal antibody 1.66 1.78 105.43
ILF9 Interleukin 1 family, member 9 4.73 5.09 106.97
CXCL9 Chemokine (C–X–C motif) ligand 9 1.85 2.04 107.97
CDK5R1 Cyclin-dependent kinase 5, regulatory subunit 2.41 2.55 109.19
TNFRSF21 Tumor necrosis factor receptor superfamily 21 2.00 2.37 109.55
TK1 Thymidine kinase 1, soluble 1.18 1.34 110.19
CCNB1 Cyclin B1 2.55 2.89 110.80
CCNB2 Cyclin B2 1.49 1.86 111.88
STAT2 Signal transducer and activator of transcription 2 1.59 1.36 115.37
S100A7 S100 Calcium binding protein A7 1.78 1.57 115.68
STAT3 Signal transducer and activator of transcription 3 1.40 1.69 121.52
Abbreviations: LS, lesional; NL, nonlesional; W, week.
1When multiple probe sets are present, the smallest improvement is reported.
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et al., 2009). This gene has been previously reported to show
increased expression in psoriatic plaques (Reischl et al.,
2007). WNT5A was only improved by 54% at the genomic
level. By immunohistochemistry, WNT5A showed the great-
est expression in the epidermis of LS skin, with some dermal
staining (Figure 2b). There was a persistent expression by
week 12, greater than NL, and minimal staining of WNT5A in
normal skin.
RAB31 was another gene of interest that was present in
increased levels in psoriasis tissue, but did not return to NL
levels at week 12. RAB31, a member of RAS oncogene family
that has an essential role in vesicle and granule targeting (Bao
et al., 2002), showed 34% improvement at week 12.
Immunohistochemistry was performed in normal skin, NL,
and LS skin, as well as after 12 weeks of treatment (Figure 2c).
There were many RAB31-positive cells in the papillary
dermis of LS skin close to the dermo–epidermal junction,
with fewer positive cells in NL skin and at week 12. There
was minimal RAB31 expression in normal skin. In LS skin,
RAB31 was expressed on CD45þ cells, and also on some
CD11cþ myeloid DCs, mainly in the papillary dermis, and
on few CD163þ macrophages (Supplementary Figure S1 online).
Aquaporin 9 (AQP9) was another interesting downregu-
lated gene with maximal improvement of 26%. Mammalian
aquaporins are a family of 13 membrane proteins that form
water channels across cell membranes, and may transport
small solutes such as glycerol (Boury-Jamot et al., 2006).
Aquaporin 9 has been described in human skin, although its
role there is not fully understood. In normal and NL skin there
was some epidermal expression, with subtle loss of expres-
sion in LS skin, and some recovery at week 12, although not
to NL levels (Figure 2d).
Canonical pathways do not fully resolve
To obtain a global view of the RDGP in terms of pathways
rather than gene by gene, we quantified the average
improvement for a number of canonical pathways. Of 358
canonical pathways that were represented in the transcrip-
tome, several of them showedo75% improvement (selected
pathways shown in Table 3). For example, disease genes in
the Leptin pathway improved by only 56%. This could be
important as leptin is considered to be partially responsible
for obesity (Kelesidis et al., 2010), and recently, there has
been an association with psoriasis and metabolic syndrome
Table 3. Resolution of cellular gene sets and canonical pathways at the end of treatment
Name Mean n Description Reference
Cellular gene sets
Keratinocytes 105.14 85 Upregulated in keratinocytes (Haider’s cell maps) (Haider et al., 2007).
Terminal differentiation genes 93.78 17 Genes representing epidermal differentiation
complex and cornified envelope
(Guttman-Yassky et al., 2009)
Keratinocytes + TNF 98.37 179 Upregulated in TNF-treated keratinocytes
at 1.5-fold change and FDRo0.1
(Zaba et al., 2010)
T cells 87.73 25 Upregulated in T cells (Haider’s cell maps) (Haider et al., 2007)
Immature DCs 89.36 8 Upregulated in immature DCs (Haider’s cell maps) (Haider et al., 2007)
Mature DCs 97.61 19 Upregulated in mature DCs (Haider’s cell maps) (Haider et al., 2007)
Inflammatory myeloid DCs 97.30 41 Upregulated in BDCA1 cells (vs BDCA1+) from
psoriasis lesions at 2-fold change and FDRo0.1
(Zaba et al., 2010)
Macrophages 91.10 14 Upregulated in macrophages (Haider’s cell maps) (Haider et al., 2007)
Genes in pathway
(% improvement)
Canonical pathways (C2 CP collection from MsigDB)
ST_MYOCYTE_AD_PATHWAY 51.70 6 Cardiac myocytes have a variety of adrenergic
receptors that induce subtype-specific signaling
effects
TPR3 (41.37), ITPR3 (65.9), ITPR2
(49.19), ITPR2 (70.8), ITPR2 (38.44),
EPHB2 (44.51)
LEPTIN PATHWAY 55.62 5 Leptin is secreted by adipose tissue that in skeletal
muscle promotes fatty acid oxidation and insulin
sensitivity, decreases lipid content
LEP (110.95), LEPR (69.68), LEPR
(26.49), LEPR (43.29), LEPR (27.71),
ST_WNT_CA2_CYCLIC_
GMP_PATHWAY
65.61 7 Some Wnt glycoprotein/Frizzled receptor
interactions increase intracellular calcium and
decrease cGMP
ITPR3 (41.37), ITPR3 (65.9), ITPR2
(49.19), ITPR2 (70.8), ITPR2 (38.44),
ITPKB (100.93), NFAT5 (92.66)
T CYTOTOXIC PATHWAY 76.22 4 Cytotoxic T cells release perforin and granzyme to
lyse foreign cell targets and express Fas ligand to
promote Fas-induced apoptosis
CD2 (48.72), PTPRC (87.43), PTPRC
(59.08), PTPRC (109.66)
Abbreviations: DC, dendritic cell; FDR, false discovery rate; TNF, tumor necrosis factor.
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(Azfar and Gelfand, 2008). The failure of this pathway to
improve by 100% may be related to ongoing risk for obesity
and the metabolic syndrome, even with clinical improvement
in the skin. Myocyte AD pathway only improved by 52%,
and Wnt pathway was improved by 66%, both of which
could relate to structural components in the skin or other
organs.
DISCUSSION
Psoriasis vulgaris tends to be active in focal regions of skin
for long periods of time, unless treated with an effective
therapeutic agent. However, lesions that appear to be resol-
ved by therapy also tend to recur within weeks to months
after ceasing treatment, and recurrence often involves the
same regions as prior lesions. Hence, an unresolved issue is
whether successfully treated lesions continue to express fac-
tors that favor lesion development, as compared with back-
ground skin in that patient. From the clinical perspective,
psoriasis plaques often resolve completely, except for some
pigmentary change. From histopathological assessment,
there is often complete reversal of acanthosis, disordered
terminal differentiation, and psoriasiform pattern along with
Table 4. Selected disease genes that have o75% improvement
Symbol Description LS vs NL W12 vs LS Improvement (%)
Upregulated genes that have o75% improvement
RAB311 Member RAS oncogene family 1.14 0.31 33.80
TRCB11 T-cell receptor b-constant 1 1.82 0.86 42.62
MMP 9 Matrix metallopeptidase 9 (gelatinase B, 92 kDa type IV collagenase) 1.54 0.83 46.42
CD2 CD2 molecule 1.51 0.75 48.72
LCK Lymphocyte-specific tyrosine kinase 1.23 0.77 52.59
WNT5A1 Wingless-type MMTV integration site family 2.83 1.55 54.24
CD48 CD48 molecule 1.04 0.69 57.69
IF1441 Interferon-induced protein 44 2.86 1.46 61.06
SYK Spleen tyrosine kinase 1.09 0.79 62.04
GZMA Granzyme A (granzyme 1, cytotoxic T lymphocyte) 1.73 0.97 64.34
LTB Lymphotoxin-b (TNF superfamily, member) 1.30 1.01 66.30
CD361 CD36 molecule (thrombospondin receptor) 1.89 0.67 68.20
IRF1 Interferon regulatory factor 1 1.13 0.90 68.66
HLA-DPA1 Major histocompatibility complex, class II 1.40 0.79 68.73
IFIT3 Interferon-induced protein with tetratricope 1.80 1.20 70.86
CCL2 Chemokine (C–C motif) ligand 2 1.36 1.33 73.06
IFI27 Interferon, a-inducible protein 27 2.24 1.73 73.42
CXCR4 Chemokine (C–X–C motif) receptor 4 3.05 2.40 73.54
CCL18 Chemokine (C–C motif) ligand 18 2.35 2.13 73.86
ISG20 Interferon stimulated exonuclease gene 20 1.59 1.05 74.87
Downregulated genes that have o75% improvement
MUC7 Mucin 7, secreted 2.27 0.37 15.51
LYVE11 Lymphatic vessel endothelial hyaluronan receptor 1 1.38 0.4 21.45
AQP9 Aquaporin 9 1.85 0.43 25.85
CLDN10 Claudin 10 1.38 0.43 26.01
LEPR1 Leptin receptor 1.26 0.28 26.49
CLDN8 Claudin 8 3.44 1.52 44.95
AQP5 Aquaporin 5 1.52 0.85 52.72
MMP7 Matrix metallopeptidase 7 (matrilysin, uterine) 1.17 0.68 54.83
DSG2 Desmoglein 2 1.23 0.93 56.53
Abbreviations: LS, lesional; NL, nonlesional; TNF, tumor necrosis factor; W, week.
1When multiple probe sets are present, the smallest improvement is reported.
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elimination of excess infiltrating leukocytes (Gottlieb et al.,
1995; Abrams et al., 2000; Zaba et al., 2007; Haider et al.,
2008; Johnson-Huang et al., 2010).
We present a method to more accurately define the
pathological activity at the end of effective treatment, using
microarray expression. We have defined the RDGP, as a set
of genes that did not resolve by 3 months of etanercept
treatment. This study shows four important features of
clinically resolved lesions: (1) inflammation, as defined by
expression of key cytokines and chemokines, is not com-
pletely resolved in treated lesions, although the epidermal
reaction is fully resolved; (2) there are residual dermal CD8þ
T cells; (3) structural cells of the skin continue to express
molecular alterations; and (4) some subtle features of skin
structure, for example, lymphatics, are not fully normalized
with treatment. A similar pattern of collapsed lymphatics was
seen in psoriasis lesions (Henno et al., 2009), but normal-
ization after treatment was not studied.
Tumor necrosis factor (TNF) blockade with etanercept in
psoriasis leads to two sets of early effects (Zaba et al., 2007,
2009b). First, the classic ‘‘sepsis cascade’’ pathway of TNF,
leading to IL-1 production, followed by IL-6 and IL-8
cytokines, is suppressed within 1 week of starting treatment
in all patients (Zaba et al., 2009b). Second, DC activation
(presumably TNF stimulated) is rapidly decreased in respond-
ing patients, resulting in reduced production of IL-23 and
Normal
LYVE-1
WNT5A
RAB31
AQP
Nonlesional Lesional Week 12
Figure 2. Immunohistochemistry for select genes in residual disease genomic profile. Representative staining in normal, nonlesional (NL), lesional (LS) skin
samples, and in those after 12 weeks of etanercept treatment. (a) LYVE-1 showed discernible lymphatic lumen in normal and NL skin compared with collapsed
lymphatic vessels in LS skin and in those after 12 weeks of treatment. (b) WNT5A showed increased expression in LS skin and even after 12 weeks of treatment
compared with NL and normal skin. (c) RAB31 identified many positive dermal cells in LS skin, which decreased after 12 weeks of treatment but did not completely
return to NL levels. (d) AQP9 showed decreased expression in LS skin compared with NL and normal skin and after 12 weeks of treatment. Bar ¼ 100mm.
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other proinflammatory molecules (Zaba et al., 2007). Th17
and Th22 cells are also rapidly deactivated, as evidenced
by reduced IL-17, IL-22, and downstream genes (Zaba et al.,
2007). In this study, we showed that overall, CD3þ T cells
were reduced by 96% and CD11cþ DCs were reduced by
88% in skin lesions, with nearly complete elimination of
leukocytes infiltrating the epidermis. Pathogenic psoriasis
DEGs were also highly suppressed by etanercept treatment,
such that 480% of DEGs were effectively normalized.
However, TNF-targeted therapeutics modulate adaptive
immunity only indirectly; hence, major histocompatibility
complex–antigen–TCR and costimulatory interactions bet-
ween DCs and T cells resident in skin should still occur even
in the presence of full TNF blockade. We postulate that
ongoing interactions between residual DCs and T cells in
healed psoriasis plaques may lead to low levels of T-cell
cytokines and products, but below the threshold that triggers
epidermal activation and visible disease phenotype. Given
that some inflammatory circuits appear to persist at low levels
in treated lesions, it is not yet clear what are the specific
molecules and their level of expression required for an active
lesion to become recognizable by histopathology or clinical
criteria. We hypothesize that persistent IL-17 and IL-22
expression may reach a threshold wherein sufficient cyto-
kine is available to bind to IL-17 and IL-22 receptors on
keratinocytes and trigger known psoriasis genes, such as
S100A7 (psoriasin), b defensins (DEFB4), and cathelicidin
(LL37). In particular, production of LL37 and binding of
self-RNA could trigger DC activation with accumulation of
DC-LAMPþ DCs in the skin (Lande et al., 2007). Collapsed
lymphatics could lead to poor lymphatic drainage and may
increase edema in healing lesions, while also restricting T cell
and DC trafficking to draining lymph nodes, effectively
trapping activated leukocytes in the skin.
Recently, it has been shown that effector memory T cells
(TEM) are found as resident T cells within normal-appearing
skin and act as a first line of defense when skin is
rechallenged with antigen (Liu et al., 2010; Clark, 2010).
Hence, it is possible that healed psoriasis could also contain
residual ‘‘psoriasis-specific’’ TEM, and thus be ‘‘primed’’ to
expand when the right signal is given, which may lead to
site-specific inflammation. We observed that while CD3þ
cells appear to resolve almost completely in the epidermis
and dermis, bulk CD8þ cells in the dermis only showed
improvements of 64%, which could include a subpopulation
of CD8þ TEM that could be part of the residual inflammatory
signature in psoriasis. As TEM frequency is best determined by
FACS of single cell suspensions (TEM are CCR7
 CD45RAþ ),
further studies with appropriate tissue samples will be needed
to answer this question.
The clearance of epidermal T cells but persistence of
some dermal CD8þ T cells is consistent with the proposed
pathogenic role of CD8þ T cells in psoriasis (Kryczek et al.,
2008). This is supported by murine xenotransplant studies of
human NL skin, which showed that blockade of T cells into
the epidermis by inhibiting a1b1 integrin, prevented epider-
mal hyperplasia and the development of psoriasis lesions
(Conrad et al., 2007).
We acknowledge several limitations of this study. First,
biopsies were available only until 12 weeks of treatment.
Potentially, longer treatment could lead to additional
genomic improvements, but at some point, continued
expression of DEGs might represent a ‘‘molecular scar’’ of
inflammation in the skin. Second, some genomic effects
produced by etanercept might be agent specific, and future
studies will be required to compare treatment outcomes with
different therapeutic agents. It will be interesting to ascertain
the relationship between quantitative or qualitative suppres-
sion of DEGs and remission periods on therapeutic disconti-
nuation. It is important to determine whether the psoriasis
transcriptome could be fully reversed by any treatment,
should a durable response or ‘‘cure’’ of psoriasis be possible.
Third, to the extent that psoriasis NL skin has abnormal gene
expression (Gudjonsson et al., 2009), it would be interesting
to study whether antiinflammatory treatment affects NL skin
gene sets. Fourth, inflammatory products in the skin might
have ‘‘systemic’’ inflammatory effects that modulate psor-
iasis, such as recently described comorbidities (Davidovici
et al., 2010), and hence it will be important to study other
tissues that might be impacted by targeted immune inhibitor.
In conclusion, we suggest that histological resolution of
psoriasis skin lesions is not accompanied by full resolution of
molecular alterations, as assessed by gene profiling. We
present a set of genes that represent the RDGP, genes that do
not go back to NL levels. Other inflammatory diseases such
as rheumatoid arthritis, psoriatic arthritis, or inflammatory
bowel disease are destructive or scarring at the primary sites
of involvement, whereas psoriasis is not. Even so, many of the
questions that we raise for psoriasis—the extent to which a
disease process can be reversed or progression prevented and
whether a real cure is possible—are shared across common
inflammatory diseases in humans.
MATERIALS AND METHODS
Patients
A total of 20 adult patients with moderate-to-severe psoriasis were
treated with etanercept (50mg) subcutaneously twice weekly for 12
weeks, as part of a clinical trial (no. NCT00116181). The clinical
trial was conducted according to the principles expressed in the
Declaration of Helsinki, and an informed consent for their
information to be stored in the hospital database and used for
research was obtained from all patients in written form. This research
was conducted under protocol JKR-0542 approved by the Rock-
efeller University institutional review board.
The clinical and histological response of these 20 patients was
previously published (Zaba et al., 2007). Patients were defined
histologically as ‘‘responders’’ if the serial biopsies of an index
plaque showed return of epidermal thickness and keratin 16
immunohistochemistry to NL levels.
Gene expression data
RNA from skin biopsies of 15 patients was hybridized to Affymetrix
HGU133a2 chips (Affymetrix, Santa Clara, CA) as described (Zaba
et al., 2009b). Microarray is deposited at the Gene Expression
Omnibus repository (GSE11903). Probe set annotation was obtained
with hgu133a2.db package (version 2.3.5) from Bioconductor
(www.bioconductor.org).
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Statistical analysis
In a prior publication (Zaba et al., 2009b), a mixed-effect linear
model with ‘‘patient’’ as random effect was used to model gene
expression using interaction time response. From this model,
the treatment effect at 12 weeks was estimated for responders using
the limma package from Bioconductor.
Psoriasis-related genes (Sua´rez-Farin˜as et al., 2010) were
analyzed at the end of treatment to evaluate return to NL. For each
disease gene, we quantified improvement after 12 weeks of
treatment as:
Improvement ¼ 100 log2 X12=XLSð Þ
log2 XLS=XNLð Þ
where XLS, XNL, and X12 are the expression values at LS, NL, and 12
weeks of treatment, respectively. RDGP is defined as the genes with
improvement below 75%.
We used gene set approach to quantify the average improvement
for a collection of pathways (Table 3). We included the canonical
pathways (C2 CP) from MDigDB (http://www.broadinstitute.org/
gsea/msigdb) and several gene sets developed by our group (Haider
et al., 2007; Guttman-Yassky et al., 2009).
Reverse transcriptase PCR, immunohistochemistry, and
immunofluorescence
Skin biopsies for leukocyte markers were stained and counted and
PCR was carried out in a standard manner (Zaba et al., 2007). Most
of these results had been published (Zaba et al., 2007) and are
reanalyzed here to determine mean improvement after 12 weeks of
treatment. Standard procedures were followed for immunohisto-
chemistry (n¼ 6), immunofluorescence (n¼ 3), and CD8þ cell
counts (n¼ 6), as previously described (Zaba et al., 2009a).
Antibodies used for immunohistochemistry and immunofluores-
cence are listed in Supplementary Table S2 online. Images were
acquired using appropriate filters of a Zeiss Axioplan 2 widefield
fluorescence microscope with Plan Neofluar 20 0.7 numerical
aperture lens (Carl Zeiss, Thornwood, NY) and Hamamatsu Orca ER-
cooled charge-coupled device camera (Hamamatsu, Bridgewater,
NJ), controlled by METAVUE software (MDS Analytical Techno-
logies, Downington, PA). Immunohistochemistry was conducted
in batches for paired samples and representative staining is shown.
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